Laboratory screening and diagnosis of von Willebrand's disease

Clinical Laboratory

Volumn 48, Issue 7-8, 2002, Pages 385-393

  Schlammadinger, Ágota ^a   Boda, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

"in vitro bleeding time" screening tests; Laboratory diagnosis; von Willebrand's disease

Indexed keywords

ANTIFIBRINOLYTIC AGENT; DESMOPRESSIN; HORMONE; THROMBOCYTE CONCENTRATE; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; BLEEDING DISORDER; DELIVERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FATALITY; HUMAN; LABORATORY TEST; PREOPERATIVE CARE; QUALITY OF LIFE; SCREENING TEST; TIME; VON WILLEBRAND DISEASE;

ALGORITHMS; BLOOD COAGULATION TESTS; DECISION MAKING; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0036319776     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Epidemiological investigation of the prevalence of von Willebrand's disease
2. Hereditär pseudohemofili
3. Immunologic differentation of classic hemophilia (FVIII deficiency) and von Willebrand's disease. With observations on combined deficiencies of antihemophilic factor and proaccelerin (Factor V) and on an acquired anticoagulant against antihemophilic factor
4. Amino acid sequence of human von Willebrand factor
5. Treatment of von Willebrand's disease
6. von Willebrand factor
7. Biochemistry and genetics of von Willebrand factor
8. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
9. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor
10. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow
11. Von Willebrand factor
12. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor
13. Platelets and shear stress
14. Impact, diagnosis and treatment of von Willebrand disease
15. Von Willebrand disease: Recent advances in pathophysiology and treatment
16. The effect of ABO blood group on the diagnosis of von Willebrand disease
17. Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor
18. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis
19. A revised classification of von Willebrand disease
20. Molecular mechanism and classification of von Willebrand disease
21. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Åland islands
22. Molecular genetics of von Willebrand disease
23. Gene defects in 150 unrelated cases with type 2 von Willebrand disease: From the patient to the gene
24. Vicinal cysteines in the prosequence play a role in the von Willebrand factor multimer assembly
25. Defective dimerization of von Willebrand factor subunits due to a Cys → Arg mutation in type IID von Willebrand disease
26. Acquired von Willebrand syndrome: From pathophysiology to management
27. A critical reappraisal of the bleeding time
28. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases
29. The bleeding time does not predict surgical bleeding
30. Bleeding time and bleeding: An analysis of the relationship of the bleeding time test with parameters of surgical bleeding
31. The clinical usefulness of the preoperative bleeding time
32. Description of an in vitro platelet function analyzer - PFA-100™
33. Characterization of an in vitro platelet function analyzer, PFA-100™
34. PFA-100™ system: A new method for assessment of platelet dysfunction
35. Evaluation of the PFA-100® system in the diagnosis and the therapeutic monitoring of patients with von Willebrand disease
36. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease
37. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates
38. The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von Willebrand concentrate in type III von Willebrand disease
39. A comparison of the effects of aspirin on bleeding time measured using the Simplate™ method and closure time measured using the PFA-100™ in healthy volunteers
40. Performance of the platelet function analyser PFA-100® in testing abnormalities of primary haemostasis
41. Systemic inflammation increases shear stress-induced platelet formation measured by the PFA-100
42. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: Filter blockage and the long bleeding time in von Willebrand's disease
43. Anti-glycoprotein Ib causes platelet aggregation: Different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer
44. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test
45. A sensitive ELISA for von Willebrand factor (vWf:Ag)
46. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
47. A new automated method for von Willebrand factor antigen measurement using latex particles
48. Laboratory testing for von Willebrand's disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey
49. A method for assaying von Willebrand factor (ristocetin cofactor)
50. Study of platelet agglutination induced by the antibiotics of the vancomycin group: Ristocetin, ristomycin, actinoidin and vancomycin
51. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease
52. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use
53. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor
54. An ELISA test for the binding of von Willebrand antigen to collagen
55. The evalution of factor VIII binding activity of von Willebrand factor by means of an ELISA method: Significance and practical implications
56. Venom agglutinin: An activator of platelet aggregation dependent on von Willebrand factor